Get the Stockscreener App
5.06
12.69%
0.57
Pre-market:
5.05
-0.010
-0.20%
Taysha Gene Therapies Inc stock is traded at $5.06, with a volume of 5.02M.
It is up +12.69% in the last 24 hours and up +18.50% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.49
Open:
$4.82
24h Volume:
5.02M
Relative Volume:
0.80
Market Cap:
$1.39B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-14.17
EPS:
-0.3571
Net Cash Flow:
$-82.52M
1W Performance:
+4.12%
1M Performance:
+18.50%
6M Performance:
+81.36%
1Y Performance:
+106.11%
1-Day Range:
$4.645
$5.095
1-Week Range:
$4.03
$5.095
52-Week Range:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.06 | 1.23B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Taysha Gene Therapies (TSHA) Upgraded to Buy by Goldman Sachs - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7%Still a Buy? - MarketBeat
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - Seeking Alpha
Taysha Gene Therapies (TSHA) Receives Buy Rating from Goldman Sa - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 6.5% on Insider Selling - MarketBeat
How Taysha Gene Therapies Inc. stock reacts to oil prices2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies Insider Sold Shares Worth $1,695,906, According to a Recent SEC Filing - marketscreener.com
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m - Investing.com Canada
TSHA FY2026 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
How analysts rate Taysha Gene Therapies Inc. stock todayQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - BỘ NỘI VỤ
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Using Bollinger Bands to evaluate Taysha Gene Therapies Inc.Portfolio Return Report & Growth-Oriented Investment Plans - newser.com
Custom watchlist performance reports with Taysha Gene Therapies Inc.2025 Geopolitical Influence & Fast Entry Momentum Alerts - newser.com
Will Taysha Gene Therapies Inc. stock recover after recent dropWeekly Risk Report & Safe Capital Preservation Plans - newser.com
How Taysha Gene Therapies Inc. stock benefits from strong dollarJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutionsJuly 2025 Technicals & Free Long-Term Investment Growth Plans - newser.com
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? - MSN
11 Must-Buy Penny Stocks to Buy Now - Insider Monkey
Is Taysha Gene Therapies Inc. stock near bottom after declineJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - newser.com
Can Taysha Gene Therapies Inc. hit a new high this monthTrade Ideas & Weekly High Momentum Picks - newser.com
Can Taysha Gene Therapies Inc. stock sustain institutional interestJuly 2025 Retail & Short-Term Trading Alerts - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Detecting support and resistance levels for Taysha Gene Therapies Inc.Market Performance Summary & Real-Time Stock Entry Alerts - newser.com
Will a bounce in Taysha Gene Therapies Inc. offer an exitJuly 2025 Technicals & Real-Time Volume Triggers - newser.com
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock - Investing.com Canada
Why Taysha Gene Therapies Inc. stock is rated strong buyRate Hike & Precise Swing Trade Entry Alerts - newser.com
Taysha Gene Therapies Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):